Sources of Public Non-Dilutable Funding & Export Support to UK … · 2016-12-16 · Partnering - BioTrinity • BioTrinity™ is Europe’s leading Investment & Bio-partnering Conference

Tuesday 6 December 201618:30 – 22:00

Sources of Public Non-Dilutable Funding & Export Support to UK R&D CompaniesIn collaboration with the West Sussex Health & Life Sciences Cluster (WSHLSC)

OBN BioTuesday

19:00 Welcome, John Harris, CEO, OBN

19:15 Welcome from Louise Goldsmith, Leader of West Sussex County Council, West Sussex County Council

19:20 Keynote presentations:

SME Instrument and Eurostars, Jane Watkins, National Contact Point, Horizon 2020

Growing Your Business Overseas, Mitzi Swanson, International Trade Adviser, Life Sciences, Department of International Trade

Funding Opportunities, Michael Sullivan, Innovation Lead, Advanced Therapies, Innovate UK

Funding Opportunities From i4i NIHR, Dr Raffaella Roncone, Senior Project Manager, Innovations Directorate, NIHR

20:30 Panel discussion

22:00 Drinks and networking

Programme

Dr. John Harris CEOOBN

John G. HarrisCEO, OBN (UK) Ltd.

Agenda

• About OBN• Clusters• Disadvantages of Dilutable

Funding• Some Sources of Non-

Dilutable Funding• Running Order of the

Evening

About OBN

Supporting Innovative Life Sciences Companies

Network | Partner | Purchase | Advise | Train | Advocate

• The largest not-for-profit R&D company membership organisation in the UK

• Established 1997, 15 employees, 4 PhDs.• 400+ member companies located across the Golden Triangle of

Oxford, London, Cambridge and beyond to Manchester, Nottingham, Midlands, South Coast, & Scotland

• Contact base > 9,500 companies & LS professionals• Covering Biotech, Pharma, Veterinary, Medtech & Digital Health

Networking - Events (1)GENERAL EVENTS FOR MEMBERS

BioTuesdays: Evening networking events with 3+ speakers / panellists on a topic of business, finance or scientific interest, followed by 1.5 -2 hours of networking over wine and canapés. Typically 70-150 delegates depending on venue capacityLocations include Oxfordshire, London, Cambridge, Manchester, Nottingham, Coventry, Birmingham, South Coast

BioThirstdays: Informal networking evenings open to the whole life sciences community, held at various national venues. Link in to the local community, reconnect with existing associates, meet new contacts from the life sciences community

OBN Summer Drinks Reception: The annual summer gathering usually takes place at a prestigious venue in Oxfordshire allowing plenty of informal networking over wine and canapés

OBN Christmas Event: A sparkling drinks reception and networking event celebrating the run up to Christmas & New Year

Unrivalled opportunities to connect with Life Sciences R&D companies, mid-large pharma, their corporate partners & supporters, & the investor community

And Member discounts for a range of other national & international events

Networking – Events (2)EXCLUSIVE EVENTS

Senior Executive Clubs: Unique peer-to-peer networking forum for life sciences senior executives of our Member companies, typically CEO, CFO, COO or other C-level, SVP/VP/DVP, Director, site head or other senior decision makers

Senior Executive Dinners: These annual dinners, in each of London, Oxford and Cambridge, are by invitation only and offer an evening of relaxed networking with senior executives of the highest calibre. Connect and reconnect with some of the most influential science based R&D companies and investors for a networking reception followed by a three-course meal and fine wine

Annual Awards Event: The OBN Annual Awards is a must-attend prestigious black-tie awards evening celebrating outstanding achievements in the UK life sciences sector over the preceding year Attended by over 250 influential industry players it is the place to network, celebrate and spot the leading and emerging companies in the sector. This year’s awards took place on 6th October 2016, at the impressive Town Hall in Oxford

www.obn-awards.com

Networking - Events (3)

• Partner 4 Pharma™ are customised OBN events designed to connect major pharma companies with small biotech's and early-stage start-ups from across the UK

• Relevant to Pharma companies interested in meeting with companies and entrepreneurs to build relationships and explore in-licensing or acquisition opportunities

• OBN works directly with a Pharma company to organise an agenda, identify and invite relevant attendees, provide a suitable venue and facilitate one-to-one meetings to maximise productivity and deliver the Pharma company’s goals

EXCLUSIVE EVENTS

Partnering - BioTrinity

• BioTrinity™ is Europe’s leading Investment & Bio-partnering Conference

• Additional Scientific Fringe Events, Poster Sessions, and large Exhibition space enhance value for R&D company participation

• Over 1040 delegates from 625 companies representing 30 countries (2016)

• > 180 investors including Angels, Private, VC’s, Corporate, Institutional, Strategic, & Big-Pharma from 16 countries

• Showcasing 90+ innovative R&D companies• 10+ Expert Panels & Workshops• Prestigious Investor Dinner (limited to 100)• Generous discounts for Members

www.biotrinity.com

Purchasing - OBN Consortium

• UK’s most comprehensive and cost-effective group purchasing solution for Life Sciences companies

• Average savings up to 45% against list price• Big or small, office or laboratory – any type of

business saves money• Low cost of entry – all OBN Full Members

eligible to take part• Sixty Member companies together saved more

than £4 million in last two years• Managed by full-time, in house Senior Buyer• Capital expenditure advice• Negotiation service• Guidance and support on e-Procurement• New suppliers regularly added

Advice

Member Advice• Introduce and match members with

industry contacts, academia, partners or funding entities

• Helping members find a suitable site or location for their business

• UK Bio-Industry remuneration survey• Future property needs survey

OBN Consulting• Bespoke projects• Cluster analysis, reports and interactive

maps• Facilitate business development targeting• Builds expertise

Training

• High level professional training tailored to the specific needs and requirements of life sciences staff

• Qualified & highly experienced trainers expert in their field, delivering to small groups (up to 20)

• Topics include Introduction to the Drug Discovery Industry, Pitching to Investors, Types of Funding, Entrepreneurship & Business Skills in Life Sciences

• Bespoke training requirements can be arranged as required

Promoting the interests of innovative companies

• First to call for biomedical catalyst extension• Consultation response exercises• Direct exposure to Office of Life Sciences, UKTI,

Academic Health Science Network, MedCity & others

• Secretariat and support service for letters to ministers

• A range of OBN SIG’s to focus & drive advocacy• Local roots, national influence• Collaborations with ABPI, ABHI, BIA & others to

co-ordinate and enhance advocacy at a national level

Advocacy – range of activities

Clusters

• Life Science organisations prosper when embedded within recognised clusters with an integrated support system and dynamic business networks

• An integration agent is required to foster and develop collaborative & networking opportunities between these organisations and act as facilitator and the ‘glue’ that holds the initiative together

• OBN acts as that glue

• People have to believe they are part of a cluster

Identity Focus Competitive advantage Promotion

Follow-on investors dislike debt, especially convertible

Preferential conversion terms and anti-dilution clauses will likely act to the detriment of other investors

Security will likely be over the “crown jewels” leaving other investors potentially disadvantaged in a crisis

Other shareholders will not be equal Tax treatment may be challenging Accounting treatment will eventually be a nightmare And should a stock market listing arrive, multiple

valuations are likely to be required

Disadvantages of dilutable funding?

UK MRC MICA project Wellcome Trust seeding drug discovery Biomedical Catalyst (BMC), MRC, Innovate UK / Catapults,

NIHR / i4i programme, Export Support (DIT)

EU Framework Programme - Strong incentive to include SME's Usually basic academic research but can support company activities EU Innovative Medicines Initiative (IMI)

US NIH … open to UK companies

Charities - sector specific e.g. Michael J Fox, Bill Gates

Some sources of N-D funding

18:30 Registration and networking 19:00 Welcome from OBN (John Harris) 19:15 Welcome and Introduction from WSCC (Louise Goldsmith) 19:20 – 20:00 Key note presentations: Jane Watkins – National Contact Point, Horizon 2020 – SME Instrument &

Eurostars Mitzi Swanson – International Trade Adviser – Life Sciences, Department of

International Trade – Growing your business overseas Michael Sullivan – Innovation Lead – Advanced Therapies, Innovate UK –

Funding opportunities from Innovate UK Raffaella Roncone – Senior Project Manager, NIHR – Funding opportunities

from i4i 20:00 Panel Discussion & questions 20:30 Networking over drinks and canapes 22:00 Evening close

Running order

OBN BioTuesday: Sources of Public Non-Dilutable Funding & Export Support to UK R&D Companies

Louise GoldsmithLeader of West Sussex County Council


Jane WatkinsNational Contact PointHorizon 2020

SME Instrument and Eurostars

Jane Watkins H2020 National Contact Point for SMEsNational Programme Coordinator for Eureka Eurostars

SME Instrument and Eurostars

OBN 06/12/2016

What is an SME?

• To count as an SME, your organisation must be engaged in an economic activity and must have:– fewer than 250 employees; and– an annual turnover of no more than €50 million and/or– an annual balance sheet of no more than €43 million.

• Whether you count as an SME may depend on how you count your workforce, turnover or balance sheet.

• For more details:– http://ec.europa.eu/enterprise/policies/sme/files/sme_defini

tion/sme_user_guide_en.pdf

SME self-assessment wizardBased on organisational financial data and headcount

• Shareholders/shareholdings may affect status (non-autonomous)• Assessment optional and only required if participating in SME specific actions

• Can’t apply for an SME action if entity not validated as SME in last 2 years• The wizard produces an instant result and summary of data• The wizard isn’t a model of clarity…• Typical issues: status expired, no economic activity, applicants leave it too late, applicants believe they are SMEs but aren’t!

SME definition:http://ec.europa.eu/enterprise/policies/sme/files/sme_definition/sme_user_guide_en.pdf

Beneficiary register user manual:http://ec.europa.eu/research/participants/data/support/manual/urf_sme_wizard_guidance.pdf

Key Features of the SME Instrument

• Targeted at all types of innovative SMEs showing a strong ambition to grow.

• Only ‘for profit’ SMEs allowed to apply for funding .• Competitive, EU dimension ‐ only the best ideas pass.• Market‐oriented, close‐to‐market activities (TRL 6).• Embedded in societal challenges and key enabling technologies.• Evaluators: market perspective.• Time to grant: 400 days in 2008 ‐ > Phase 1 95 days Phase 2 170 days. • Sole SME can apply.

TRL 1 TRL 2 TRL 3 TRL 4 TRL 5 TRL 6 TRL 7 TRL 8 TRL 9

Phase 1Grant support of €50,000 (lump

sum) + coaching

Phase 2Grant of €0.5m – 2.5m

70% funding + coaching

Phase 3Risk Finance

(Public/Private)

Project: 6 Months Project: 12 – 24 Months

Concept & Feasibility Assessment DemonstrationMarket Replication R&D

Commercialisation

Concept to Market-Maturity Market-Maturity to Market Launch

Proof of ConceptProve technical & commercial viabilityExplore IP regimeDesign StudyDevelop pilot applicationRisk assessment

Demonstrate Commercial PotentialPrototypingTestingPilotingMiniaturisationScaling-UpApplication Development

Go-To-MarketEU Quality LabelInvestment Readiness TrainingSME window in EU financial facilities (Debt & Equity)Link to Public Procurement Networks

Outcome: Elaborated Business Plan Outcome: Commercialisable Output Outcome: Market Success

Phase 3Risk Finance (Public/Private)

Specific Calls SME Instrument 2016/17

• SMEInst‐01‐2016‐2017: Open Disruptive Innovation Scheme• SMEInst‐02‐2016‐2017: Accelerating the uptake of nanotechnologies advanced materials or advanced

manufacturing and processing technologies by SMEs• SMEInst‐03‐2016‐2017: Dedicated support to biotechnology SMEs closing the gap from lab to market• SMEInst‐04‐2016‐2017: Engaging SMEs in space research and development

• SMEInst‐05‐2016‐2017: Supporting innovative SMEs in the healthcare biotechnology sector•• SMEInst‐06‐2016‐2017: Accelerating market introduction of ICT solutions for Health, Well‐

Being and Ageing Well

• SMEInst‐07‐2016‐2017: Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri‐food and bio‐based sectors

• SMEInst‐08‐2016‐2017: Supporting SMEs efforts for the development ‐ deployment and market replication of innovative solutions for blue growth

• SMEInst‐09‐2016‐2017: Stimulating the innovation potential of SMEs for a low carbon and efficient energy system

• SMEInst‐10‐2016‐2017: Small business innovation research for Transport and Smart Cities Mobility• SMEInst‐11‐2016‐2017: Boosting the potential of small businesses in the areas of climate action, environment,

resource efficiency and raw materials• SMEInst‐12‐2016‐2017: New business models for inclusive, innovative and reflective societies• SMEInst‐13‐2016‐2017: Engaging SMEs in security research and development

UK Performance – Phase 1

Phase 1 Projects funded by Topic

Phase 2 submissions latest call

Phase 2 – Proposals per topic

Submission Dates 2016 ‐2017

Rolling programme so no fixed deadline referred to as cut off.Submit when ready Times are Brussels time.80% of proposals are submitted 48 hours before the cut off.

PHASE 1 PHASE 2

2016 2016

24 February 2016 17:00 3 February 2016 17:00

3 May 2016 17:00 14 April 2016 17:0

7 September 2016 17:00

15 June 2016 17:00

9 November 2016 17:00 13 October 2016 17:00

2017 2017

15 February 2017 17:00 18 January 2017 17:00

3 May 2017 17:00 6 April 2017 17:00

6 September 2017 17:00

1 June 2017 17:00

8 November 2017 17:00 18 October 2017 17:00

Most common mistakes to avoid when writing a proposal

• TRL not convincing but don’t over complicate the TRL• Too focused on the product and the technical detail rather than the

market and how the company will make money. IMPACT section is the most important section (1.5 marks weighing)

• Skills set to commercialise not present• Section 4 is not part of the evaluation 1‐3 but it gives you opportunity to

sell yourself and your company• Excellence not linked to Impact and Implementation

Need to tell a story.• Make it easy to read – how many wrote the proposal? WHO wrote the

proposal?• Don’t underestimate Phase 1

EUREKA Eurostars

The Eurostars Programme is the first European funding and support programme to be specifically dedicated to R&D performing SMEs.

Short lead‐time:(14 WEEKS from cut‐off date to funding decision)

Projects funded by the respective partners national funding bodies UK – Innovate UK

EUREKA Eurostars

• Consortium leader is an R&D‐performing SME• At least 2 partners from 2 different Eurostars participating countries• Project duration is no more than 36 months• Market introduction is foreseen within 2 years after project ends.• Research‐performing SMEs undertake minimum 50% of total R&D cost• No single country or project partner is responsible for more than 75% of the project costs• No restriction on thematic area [except military] and project managed from the bottom up• Partners in a Consortium must be separate legal and non‐linked entities

EUREKA EUROSTARS PROJECT ELIGIBILITY CRITERIA

EUREKA EUROSTARSUK PARTNER ELIGIBILITY

In the UK R & D Intensive SME’s are eligible for funding. Large companies, RTOs and Universities can participate in Eurostars projects, but must source alternative funding.

• Trading for at least 12 months. • VAT registered ‐Maintain up to date “books” or management accounts sufficient to generate a Profit and Loss account. • Revenue generation from commercial operations and/or investment to cover non‐ grant funding – at the time of application. • Sub‐contract must not exceed 20% of UK Par0cipant Project costs. • Projects must be managed by (R)SME, not subcontracted. Single entities cannot lead a project. • Funding level 60% of eligible costs – up to €360K • Maximum grant €360K per UK partner

The countries participating in Eurostars through the EUREKA network of national offices are: Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, South Africa, South Korea, Sweden, Switzerland, Turkey, United Kingdom.

Who are the Eurostars Participating States and Partner Countries?

UK Technological and market area

Practical Help• Self evaluation form

– http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/ef/h2020‐call‐ef‐sme_en.pdf

• Submission is via Participant Portal– http://ec.europa.eu/research/participants/portal/desktop/en/home.html

SMEI Video hints and tipshttp://ec.europa.eu/easme/en/news/precious‐tips‐4‐sme‐instrument‐evaluators

For Fast Track to Innovation or the SME Instrument contact Jane Watkins NCP‐[email protected] 07500051146


Mitzi SwansonInternational Trade Advisor, Life Sciences Department of International Trade

Growing Your Business Overseas

Growing your business overseas

Mitzi Swanson

International Trade Adviser –Healthcare and Bioscience

Team Manager

We help companies:• Understand how to do business overseas;

• Gain insight into global markets;

• Identify opportunities and open doors;

• Reach customers/partners not otherwiseaccessible;

• Raise their profile and credibility overseas;

• Understand the competition;

• Improve overseas marketing and communication;

• Access research to inform management decisions.

DIT’s Services for Exporters

• Market growth: Sales growth;• Increased productivity;• Reduced reliance on the UK market;• To counter seasonality;• Increase “shelf life” of products and services;• Help create and retain jobs.

Exporters:• Achieve stronger financial performance;• Are more productive and innovative than non-

exporters;• Are more resilient to an economic downturn;• Have a higher profile and more credibility;• Are more likely to stay in business.

Why should companies export?

NO – provided you:

• Understand the key features of your industry globally;

• Understand the key factors for export;• Research and carefully select your target

markets;• Understand the requirements and your

capabilities;• Take advice at all stages;• Allow or gain sufficient resources – time and

finance

Is exporting too difficult?

DIT helps companies:• Develop their export thinking;• Identify the right markets and opportunities;• Identify key export-related activities;• Reach customers/partners not otherwise

accessible;• Sign-post to other support and contacts;• Gain financial advice and guarantees;• Generally help make business happen.• Raise their profile and credibility overseas;• Understand the competition;• Improve overseas marketing and

communication;

Our advice is free, impartial and confidential.

Overcoming challenges

• DIT teams support businesses throughout the UK in identifying business opportunities around the world;

• DIT has more than 1,200 staff in over 100 overseas markets and around 400 people across UK regions, working locally with UK businesses;

• Our advisers are from the private sector, with experience in international trade/investment.

DIT has more than

1,200staff in over

100overseas markets

DIT’s global presence

South East International Trade Adviser Locations

Find them at www.exportingisgreat.com

www.great.gov.uk

South East International Trade Team T: +44 (0) 330 300 012E: [email protected]: www.gov.uk/dit

Follow us on Twitter @tradegovuk_LSE

Join our LinkedIn GroupSearch International Trade with the UK – South East

Find out about our upcoming eventswww.ditsoutheast.eventbrite.co.uk

53

Contacts


Michael SullivanInnovation Lead, Advanced Therapies Innovate UK

Funding Opportunities

Funding OpportunitiesMichael Sullivan

Innovation Lead – Advanced Therapies

OBN BioTuesday 6th Dec 2016

Sector focus to accelerate growthEmerging and Enabling Technologies

Identifying and investing in technologies and capabilities that will lead to the new products, processes and services of tomorrow

Health and Life Sciences

Focused on agriculture and food and healthcare, underpinned by bioscience and medical research and enabled by engineering and physical sciences

Infrastructure Systems

Optimising transport and energy systems and integrating them with other systems such as health and digital

Manufacturing and Materials

Advancing manufacturing readiness so R&D and technology developments increase productivity and capture value in the UK

Sector and Open funding competitions

Manufacturing and Materials9 May 2016

21 Nov 2016

<£15m

<£15m

Open6 Jun 2016

Dec 2016

<£14m

<£14m

Infrastructure Systems4 Jul 2016

Jan 2017

<£15m

<£15m

Health and Life Sciences12 Sep 2016

Feb 2017

<£15m

<£15m

Emerging and Enabling Technologies

3 Oct 2016

March 2017

<£15m

<£15m

Funding competitionsWe will also run competitions in partnership with other organisations. For all competitions see www.innovateuk.gov.uk

Biomedical Catalyst

£100 million of funding to extend and enhance the Biomedical Catalyst, supporting innovative UK life science companies to translate cutting‐edge medical technologies into commercial success

Thank You


Dr Raffaella RonconeSenior Project Manager NIHR

Funding Opportunities From i4i NIHR

Funding opportunities fromNIHR i4i Programme

6th December 2016

Raffaella Roncone

i4i Senior Programme Manager

Hanna Milewicz

i4i Programme Manager

i4i – Invention for Innovationi4i – Invention for Innovation

i4i: Who we are, what we do

• NIHR translational funding scheme• Support collaborative R&D and clinical adoption• Innovative healthcare technologies

Medical devices Active implantable devices In vitro diagnostics

• De-risk projects for follow-on investment• Led by Programme Director, Martin Hunt• Supported by a team of Programme Managers

Invention Evaluation Adoption Diffusion

i4i

i4i – Invention for Innovation

i4i Bridges the Medtech ‘Valley of Death’

Innovation RegulatoryIP & commercial strategy

NHS adoption plan

Technology that is attractive to follow-on funders and investors for commercialisation

Proof-of-concept Clinical need

Basic research produces proof of concept data

Project plan & Team

Value for money

Patient and public involvement

The Graveyard of Good Ideas


Facts & figures

2funding streams

>£80Mtotal

spend

Up to

36months

£3.25Mlargest award

93active

projects

• i4i Product Development Awards (http://www.nihr.ac.uk/funding/i4i-product development awards)

• i4i Challenge Awards (http://www.nihr.ac.uk/funding/i4i-challenge-awards.htm)


Why apply to i4i?

• Dedicated Medtech funding programme• Large funding amounts• Source of early funding for SMEs • Milestone-based awards to de-risk• Commercially oriented panel supported by peer review• Guidance and advice through RSG/IPMG• Favourable independent review by RAND1

1 ‘The NIHR Invention for Innovation (i4i) programme. A review of progress and contributions to innovation in healthcare technologies‘


i4i – "Starter for 10"

• R&D activities must be in remit• A minimum of two organisations• Lead applicant must be based in England• Projects must have demonstrated proof-of-

concept• Work packages must not include animal

studies


Stage 1 Preliminary scrutiny

Hit the deadline!

Stage 2External

peer & lay reviewers Panel

assessment

Ratification Outcome notification

Funding process


Risk mitigation path- postaward

Contracting

MonitoringProgress and financial Reports, stage-gated payments, site visits, Research Steering Group, Intellectual Property Management Group

Post‐projectmonitoring

Due diligence:• Science scrutiny• IP & Commercial scrutiny• Financial scrutiny• Legal scrutiny

Periodic catch up on advancement and generated impact


A successful application

Proof-of-concept

Clinical needand impact on NHS/patients

Innovation

Project plan&

Team

Patient and public

involvement

Regulatory IP, commercial & strategy

NHS adoption

Value for money


Fast DNA testing platform

• QuantuMDx Group Ltd, £1.1M for 3 years• Robust nanowire sensor and new

sequencing chemistry• Result in 15min, significant cost reduction• Global market for platform £100bn• Leveraged EU (€5.2M) and Angel ($8.42M)

funding• £2.0M secured from Helsinn Investment

Fund S.A. In oct 2016• Expected product launch in 2018


• Quanta Fluid Solutions Ltd, £2.4M from i4i• CE-marked home dialysis machine• Compact, user-friendly, simple cartridge system• Reduced time burden, improved survival• Estimated NHS cost savings £15k

per patient per year• Secured £45M of VC funding

Compact dialysis machine


i4i Product Development Awards: Future Call

Call 14 Launch 26th April 2017

Stage 1 deadline 7th June 2017

Invitations to stage 2 2nd August 2017

Stage 2 deadline 27th September 2017

Panel meeting 28th and 29th November 2017


i4i Challenge Awards- Mental Health: Future Call

Call Launch 11 Jan 2017Stage 1 deadline 5 April 2017Invitations to stage 2 24 May 2017Stage 2 deadline 27 September 2017Panel meeting w/c 27 November 2017Funding decision End of December at the

earliest


Thank you

i4i – Invention for InnovationNIHR Central Commissioning Facility15 Church StreetTwickenham TW1 3NL

Contact us for advice and specific guidance:T 020 8843 8080E [email protected] http://www.nihr.ac.uk/funding-and-support/funding-for-research-studies/how-to-

apply/research-programmes/invention-for-innovation/

Disclaimer: Please note that all case studies present independent research funded by the NIHR . The views are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Additional slides


i4i Active portfolio

Blood

Cancer

Cardiovascular

CongenitalEar

Eye

Generic

Infection

InflamatoryInjuries

Mental HealthMetabolicMusculoskelet

al

Neurological

Oral & Gastro

Other

Renal

ReproductionRespiratory

SkinStroke


i4i Funded applications

All AHSN regions are represented

Panel Discussion


Documents

Sources of Public Non-Dilutable Funding & Export Support to UK … · 2016-12-16 · Partnering - BioTrinity • BioTrinity™ is Europe’s leading Investment & Bio-partnering Conference